Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry

JACC: Heart Failure

Volumn 7, Issue 1, 2019, Pages 13-21

  Brunner La Rocca, Hans Peter ^a   Linssen, Gerard C ^b   Smeele, Frank J ^c   van Drimmelen, Annemarie A ^d   Schaafsma, Henk Jan ^e   Westendorp, Paul H ^f   Rademaker, Philip C ^g   van de Kamp, Hendrik J ^h   Hoes, Arno W ⁱ   Brugts, Jasper J ^j  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Twente Hospital Group   (Netherlands)

^c SLINGELAND HOSPITAL   (Netherlands)

^d AMPHIA HOSPITAL   (Netherlands)

^e GELDERSE VALLEI HOSPITAL   (Netherlands)

^f Rivas Zorggroep Beatrix Hospital   (Netherlands)

^g ZorgSaam Hospital   (Netherlands)

^h Business Unit Cardiometabolic   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

guideline adherence; heart failure; HFrEF; reduced ejection fraction; registry; treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; LABETALOL; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; PROPRANOLOL; RENIN ANGIOTENSIN SYSTEM INHIBITOR; SACUBITRIL; SOTALOL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN; FUROSEMIDE; SPIRONOLACTONE;

AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG TOLERABILITY; DRUG USE; DUTCHMAN; FEMALE; HEART FAILURE; HEART FAILURE WITH MIDRANGE EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; AGE; CHRONIC DISEASE; HEART STROKE VOLUME; MIDDLE AGED; NETHERLANDS; PATHOPHYSIOLOGY; REGISTER; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FUROSEMIDE; GUIDELINE ADHERENCE; HEART FAILURE; HUMANS; IVABRADINE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; RENIN-ANGIOTENSIN SYSTEM; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE; STROKE VOLUME;

EID: 85058705476     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2018.10.010     Document Type: Article

References (31)

1. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
2. Pfeffer, M.A., Braunwald, E., Moye, L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992), 669–677.
3. Cleland, J.G., Cohen-Solal, A., Aguilar, J.C., et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 360 (2002), 1631–1639.
4. Komajda, M., Follath, F., Swedberg, K., et al. The EuroHeart Failure Survey programme–a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 (2003), 464–474.
5. Savarese, G., Carrero, J.J., Pitt, B., et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20 (2018), 1326–1334.
6. Greene, S.J., Butler, J., Albert, N.M., et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72 (2018), 351–366.
7. Komajda, M., Lapuerta, P., Hermans, N., et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26 (2005), 1653–1659.
8. Komajda, M., Cowie, M.R., Tavazzi, L., Ponikowski, P., Anker, S.D., Filippatos, G.S., Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 19 (2017), 1414–1423.
9. Shah, B., Hernandez, A.F., Liang, L., et al. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. J Am Coll Cardiol 53 (2009), 416–422.
10. Maggioni, A.P., Dahlstrom, U., Filippatos, G., et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 15 (2013), 808–817.
11. Maggioni, A.P., Anker, S.D., Dahlstrom, U., et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15 (2013), 1173–1184.
12. Crespo-Leiro, M.G., Anker, S.D., Maggioni, A.P., et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18 (2016), 613–625.
13. McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
14. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
15. Jonsson, A., Edner, M., Alehagen, U., Dahlstrom, U., Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 12 (2010), 25–31.
16. Brugts, J.J., Linssen, G., Hoes, A.W., Brunner-La Rocca, H.P., for the investigators C-H. Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands: design and rationale of the Chronic Heart failure ESC-guideline based Cardiology practice Quality project (CHECK-HF) registry. Neth Heart J 26 (2018), 272–279.
17. McMurray, J.J., Adamopoulos, S., Anker, S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 (2012), 1787–1847.
18. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
19. Swedberg, K., Komajda, M., Bohm, M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376 (2010), 875–885.
20. DeVore, A.D., Thomas, L., Albert, N.M., et al. Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry. Am Heart J 189 (2017), 177–183.
21. Luo, N., Fonarow, G.C., Lippmann, S.J., et al. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines-Heart Failure (GWTG-HF). J Am Coll Cardiol HF 5 (2017), 305–309.
22. Fonarow, G.C., Yancy, C.W., Hernandez, A.F., Peterson, E.D., Spertus, J.A., Heidenreich, P.A., Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 161 (2011), 1024–1030.
23. Roth, G.A., Poole, J.E., Zaha, R., Zhou, W., Skinner, J., Morden, N.E., Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation. J Am Coll Cardiol 67 (2016), 1062–1069.
24. Remme, W.J., McMurray, J.J., Hobbs, F.D., et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 29 (2008), 1739–1752.
25. Flather, M.D., Shibata, M.C., Coats, A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005), 215–225.
26. Chioncel, O., Lainscak, M., Seferovic, P.M., et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19 (2017), 1574–1585.
27. Rickenbacher, P., Kaufmann, B.A., Maeder, M.T., et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 19 (2017), 1586–1596.
28. Lund, L.H., Claggett, B., Liu, J., et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20:8 (2018 Aug), 1230–1239.
29. Solomon, S.D., Claggett, B., Lewis, E.F., et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37 (2016), 455–462.
30. Kaufmann, B.A., Min, S.Y., Goetschalckx, K., et al. How reliable are left ventricular ejection fraction cut offs assessed by echocardiography for clinical decision making in patients with heart failure?. Int J Cardiovasc Imaging 29 (2013), 581–588.
31. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987), 1429–1435.